Series B financing will accelerate clinical trials and global commercialization of the company’s Symani® Surgical System

Medical Microinstruments, Inc. (MMI), a robotics company dedicated to improving clinical outcomes for patients undergoing microsurgery, today announced it has raised $75 million in Series B financing. Deerfield Management led the round with participation from new investors, RA Capital Management and Biostar Capital, as well as existing investors, Andera Partners, Fountain Healthcare Partners, Panakès Partners and Sambatech. The company also announced the addition of three new members to its board of directors.

In addition, the company announced its corporate redomicile from Italy to the United States. The recently opening Center of Excellence facility in Pisa, Italy, with nearly 100 employees will
continue to be the hub of the company’s research and development, manufacturing, and other business activities.

Proceeds from this financing round and the company’s planned U.S. presence will launch MMI into its next stage of growth as it continues its mission to improve the quality of patient care by
pushing the boundaries of microsurgery. The company seeks to expand indications and support ongoing commercialization efforts for the Symani® Surgical System in Europe where it received CE mark in 2019. MMI also intends to accelerate plans to commercialize in the U.S. and Asia- Pacific, as well as advance clinical research including securing an Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration to conduct a pivotal study. The Symani System was developed specifically to address the challenges of microsurgery and is the only system that offers NanoWrist® Instruments designed to improve a surgeon’s ability toaccess and suture small, delicate anatomy.

“This financing round, coupled with our commitment to access the U.S. market and the addition of visionary leaders to our board, is an exciting moment for the surgical robotics space,” said Mark Toland, CEO of MMI. “We’re pleased to have bridged the Atlantic with premier U.S. life science investors, and existing European investors, who share our same vision of bringing microsurgical robotics to the world.”

The company’s new board members are Andrew ElBardissi, MD, Tess Cameron and Arturo Baroncelli. Dr. ElBardissi is a partner at Deerfield Management, with extensive experience serving as a board member for innovative healthcare companies. Ms. Cameron serves as principal for RA Capital Management and currently sits on the boards of Avilar Therapeutics and Nodexus Inc. Baroncelli previously worked as a robotics business development manager for Comau and will represent MMI’s founders on the board.

“We are thrilled to add further depth and experience to the MMI Board and look forward to working with our new board members to build the robotic microsurgical space,” said Andrew Cleeland, Chairman of the Board for MMI.

“The MMI technology is one of the most significant transformational advancements in surgical robotics that we have seen,” said Dr. ElBardissi. “Having the world’s smallest wristed instruments opens up the field of ‘micro’ robotics to a completely new level of treatment spanning microsurgery for cancer, trauma, orthopedic, pediatric, and one day, neurosurgery patients. Symani will be the future of how microsurgery is performed worldwide.”

“Robotic microsurgery has enormous potential to both improve the standard of care for patients and help surgeons manage procedures that require delicate precision,” said Ms. Cameron. “I look forward to supporting MMI and its world-class team as it begins this exciting chapter.”

The Symani Surgical System is designed to improve a surgeon’s ability to repair anatomical structures such as veins, arteries, nerves and lymphatic vessels as small as 0.3 mm in diameter. The platform provides motion scaling and tremor reduction to allow precise micromovements. Its NanoWrist technology is the world’s smallest wristed instrumentation and is intended to improve a surgeon’s natural dexterity and range of motion beyond the capability of the human hand.

Share on :

More news

AVERTISSEMENT - CAUTION

TEMPS DE LECTURE : 2 MINUTES

READING TIME: 2 MINUTES


TENTATIVE DE FRAUDE : À LIRE ATTENTIVEMENT
ATTEMPTED FRAUD: READ IT CAREFULLY (English below)

ANDERA PARTNERS attire votre attention sur les tentatives de fraudes avec usurpation d’identité qui sévissent actuellement. Les techniques de phishing (ou hameçonnage) évoluent en permanence et sont de plus en plus sophistiquées.

Ces pratiques frauduleuses qui touchent ANDERA PARTNERS, invitent les particuliers à investir dans des comptes à terme et autres produits d’épargne fictifs sous l’identité d’ ANDERA PARTNERS (Andera Co-Invest notamment), et celles de ses collaborateurs et membres des organes de direction, via une adresse fictive et des appels téléphoniques.

Nous vous invitons à la plus grande vigilance si vous receviez ce type de sollicitations. ANDERA PARTNERS ne propose pas de compte à terme et n’a recours à aucun démarchage auprès du public, ni par téléphone ni par courriel.

Les fraudeurs ne manquent pas d'imagination pour piéger leurs victimes. Leurs actions visent à récupérer à leur insu et de manière indue des données financières, en incitant leurs victimes à réaliser des transactions dématérialisées.
En cas de doute, pour vous protéger et protéger ANDERA PARTNERS, nous vous invitons à :

*   Vous méfier des demandes inattendues, même si elles semblent provenir de dirigeants ou membre d’organes de direction d’ANDERA PARTNERS ;

*   Vérifier l’adresse de l’expéditeur. Les adresses électroniques des collaborateurs d’ANDERA PARTNERS utilisent un seul et même format : initialeduprénom.nom@anderapartners.com. Les adresses globales sont ainsi libellées : nomduservice@anderapartners.com ;

*   Ne jamais cliquer sur un lien vous demandant de partager des informations sensibles et ne jamais répondre à des demandes financières en ligne ;

*   Signaler tout message suspect qui vous demande une action immédiate.

La priorité d'ANDERA PARTNERS est de protéger ses clients et ses activités contre la fraude.
Si vous êtes victime d'une tentative d’escroquerie, veuillez contacter les relations investisseurs à l’adresse suivante : ri@anderapartners.com

Liens utiles :

LISTE NOIRE DES SOCIÉTÉS FRAUDULEUSES ÉTABLIE PAR L’AMF (AUTORITÉ DES MARCHÉS FINANCIERS) : https://www.amf-france.org/fr/espace-epargnants/proteger-son-epargne/listes-noires-et-mises-en-garde

VICTIME D'UNE ARNAQUE : COMMENT DÉPOSER UNE PLAINTE ? | AMF (AMF-FRANCE.ORG) : https://www.amf-france.org/fr/espace-epargnants/savoir-bien-investir/conseils-pratiques/en-cas-de-problemes/victime-dune-arnaque

_____________________________________________________________

ANDERA PARTNERS would like to draw your attention to fraud attempts involving identity theft that are currently rife. Phishing techniques are constantly evolving and becoming increasingly sophisticated.

These fraudulent practices, which affect ANDERA PARTNERS, invite individuals to invest in term accounts and other fictitious savings products under the identity of ANDERA PARTNERS (Andera Co-Invest in particular), and those of its employees and members of the management company, via a fictitious address and telephone calls.

Please be extremely vigilant if you receive this type of solicitation. ANDERA PARTNERS does not offer term accounts and does not canvass the public by telephone or e-mail.

Fraudsters do not lack imagination to trap their victims. Their actions are aimed at unknowingly and improperly recovering financial data, by encouraging their victims to carry out dematerialised transactions.
If in doubt, to protect yourself and ANDERA PARTNERS, we invite you to :

* Be wary of unexpected requests, even if they appear to come from ANDERA PARTNERS managers or members of management bodies;

* Check the sender's address. The e-mail addresses of ANDERA PARTNERS employees use a single format: initialeduprénom.nom@anderapartners.com. Global addresses are written as follows: nomduservice@anderapartners.com ;

* Never click on a link asking you to share confidential information and never respond to online financial requests;

* Report any suspicious message that asks you to take immediate action.

ANDERA PARTNERS' priority is to protect its customers and its business against fraud.
If you are the victim of a fraud attempt, please contact Investor Relations at the following address: ri@anderapartners.com

This will close in 0 seconds